By Fineline Cube Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced the presentation of compelling clinical data for bulumtatug fuvedotin (BFv, 9MW2821), its Nectin-4-targeting antibody drug conjugate (ADC), at the 2026 European Society for Medical Oncology Gynecological Oncology Annual Meeting (ESMO-GC). The results demonstrate unprecedented survival outcomes in heavily pretreated recurrent or metastatic cervical cancer patients and remarkable efficacy in combination with immunotherapy for treatment-naïve patients.
Clinical Data Highlights
Monotherapy Phase I/II Study – Heavily Pretreated Population
| Parameter | Result |
|---|---|
| Efficacy-Evaluable Patients | 53 patients |
| Median Overall Survival (mOS) | 19.4 months |
| 24-Month OS Rate | 49.1% |
| Subgroup Analysis | 31 patients (prior platinum + checkpoint inhibitor) |
| mOS (Subgroup) | Not yet reached |
| 24-Month OS Rate (Subgroup) | 51.1% |
Combination Phase Ib/II Study – Treatment-Naïve Population
| Parameter | Result |
|---|---|
| Regimen | 9MW2821 + toripalimab (anti-PD-1) |
| Patient Population | Treatment-naïve recurrent/metastatic cervical cancer |
| Objective Response Rate (ORR) | 80.0% |
| Disease Control Rate (DCR) | 100% |
Product Profile & Mechanism
- Target: Nectin-4 – highly expressed in cervical, urothelial, and other solid tumors
- Technology Platform: Proprietary ADC platform with optimized linker-payload chemistry
- Therapeutic Rationale: Nectin-4 overexpression in cervical cancer provides tumor-selective delivery of cytotoxic payload
- Combination Synergy: Enhanced anti-tumor activity when combined with PD-1 inhibition through complementary immune activation mechanisms
Strategic Market Impact
- Cervical Cancer Burden: Globally, 604,000 new cases annually, with limited effective options for recurrent/metastatic disease
- Survival Benchmark: Current standard therapies achieve mOS of 12–16 months in similar populations; BFv’s 19.4-month mOS represents significant improvement
- Combination Potential: 80% ORR in treatment-naïve patients could redefine first-line standards if confirmed in larger studies
- Competitive Differentiation: Among the most advanced Nectin-4 ADCs globally, competing with Padcev (enfortumab vedotin) but demonstrating superior survival data in cervical cancer specifically
Development Strategy & Global Context
The dual-track development approach—monotherapy in refractory settings and combination in frontline—maximizes commercial potential across the entire cervical cancer treatment continuum. Mabwell’s data positions 9MW2821 as a potential best-in-class Nectin-4 ADC, particularly in gynecological oncology where Padcev has limited clinical data.
Industry analysts note that the 51.1% 24-month survival rate in checkpoint inhibitor-refractory patients addresses one of the most challenging clinical scenarios in cervical cancer management. The combination data suggests potential for rapid regulatory pathway acceleration given the unprecedented response rates.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech